2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…2017 American Transplant Congress
Nonmelanoma Skin Cancer Rates Are Not Affected by Chronic HIV(+) or HCV(+) Infection in Organ Transplant Recipients.
Dermatology, Drexel, Philadelphia
Purpose: HIV and HCV are two immune dysregulatory processes that may exacerbate the risk of nonmelanoma skin cancer (NMSC) in organ transplant recipients (OTR), a…2017 American Transplant Congress
A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers.
Background: HCV cirrhosis is the leading indication for liver transplantation in the U.S. The development of direct acting anti-viral agents (DAAs) has changed the approach…2017 American Transplant Congress
A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.
Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who…2017 American Transplant Congress
Does Cirrhosis Regress in HCV Liver Transplant Recipients Achieving Sustained Virologic Response in the Era of Direct-Acting Antiviral Agents?
Background: Treatment with direct-acting antiviral agents (DAAs) in HCV patients is associated with high sustained virologic response (SVR) rates. It is hoped that cirrhosis regresses…2017 American Transplant Congress
Hepatitis C Genotypes Among Deceased Organ Donors in the United States.
1University of Pennsylvania, Philadelphia, PA; 2Gift of Life, Philadelphia, PA
Background: HCV is one of the leading causes of liver disease in the US. 5% of deceased organ donors are HCV+ and HCV infection is…2017 American Transplant Congress
Deceased Donors with a History of IV Drug Use and Donor Derived Hepatitis C Virus.
1OPTN Ad Hoc Disease Transmission Advisory Committee, Richmond, VA; 2UNOS, Richmond
Introduction:In 2015, the CDC reported a 172% increase in heroin-related deaths from 2010 to 2013. Deceased donors with IV drug use (IVDU) are at increased…2017 American Transplant Congress
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Indiana University Health, Indianapolis
Background: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. The…2017 American Transplant Congress
HCV+ Waitlist Candidates More Likely to Die Waiting for Kidney Transplant from HCV- Donor.
1University of Alabama at Birmingham, Birmingham; 2University of Pennsylvania, Philadelphia
Background: HCV-infected ESRD patients derive a significant survival benefit from kidney transplantation (KT) over remaining on dialysis. Given the high mortality rates on dialysis and…2017 American Transplant Congress
Total Pancreatectomy and Islet Autotransplantation into the Liver of a Patient with Previous Hepatitis C Infection.
Hepatic parenchymal disease such as hepatitis has been considered a relative contraindication to islet transplantation as the islets are infused into the liver. Islet transplantation…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 28
- Next Page »